Quick Answer
REVELATION BIOSCIENCES, INC. reported Net Income Loss of -$8.91 million for the year ending 2025.
- REVELATION BIOSCIENCES, INC. showed an increase of +40.7% in Net Income Loss from 2024 to 2025.
- This data is from REVELATION BIOSCIENCES, INC.'s annual report (Form 10-K), filed with the SEC on February 26, 2026.
- XBRL data for this metric is available from 2019 to 2025 (8 years of filings). Earlier data may not exist in machine-readable XBRL format as companies adopted electronic filing at different times.
- Quarterly values from 10-Q filings: Q1 2021: -$2.61 million | Q2 2021: -$2.47 million | Q3 2021: -$3.04 million | Q1 2022: -$6.62 million | Q2 2022: -$1.83 million | Q3 2022: -$1.17 million | Q1 2023: $6.16 million | Q2 2023: -$1.45 million | Q3 2023: -$2.63 million | Q1 2024: -$2.68 million | Q2 2024: -$8.39 million | Q3 2024: -$2.24 million | Q1 2025: -$2.05 million | Q2 2025: -$2.44 million | Q3 2025: -$1.91 million.
- Over the full 8 years of available data (2019 to 2025), REVELATION BIOSCIENCES, INC.'s Net Income Loss has declined by 244,915.1%.
- Historical annual values: Fiscal year 2025: -$8.91 million | Fiscal year 2024: -$15.04 million | Fiscal year 2023: -$120.3 thousand | Fiscal year 2022: -$10.83 million | Fiscal year 2021: -$11.99 million | Fiscal year 2020: -$1.63 million | Fiscal year 2019: -$3.6 thousand | Fiscal year 2019: -$3.6 thousand.
- Data sourced from SEC EDGAR public filings as of August 8, 2026.
Last verified: